Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Status: Recruiting
Phase: Phase 2
Diagnosis: Non-Hodgkin's Lymphoma
NCT ID: NCT01661881 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-168

 

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational combination of drugs to learn whether the combination of drugs works in treating a specific cancer. "Investigational" means that the combination of drugs is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the combination of drus is effective for treating different types of cancer. It also means the FDA has not yet approved this combination of drugs for your type of cancer.

 

Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital

Overall PI:
Philippe Armand, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Dana-Farber Cancer Institute: Kathleen McDermott, kmcdermott@partners.org

Eligibility Criteria

Inclusion Criteria: - Mandatory pathologic review of the diagnostic specimen(s) at Brigham and Women's Hospital or Massachusetts General Hospital - Measurable disease - Candidate for ASCT Exclusion Criteria: - Prior anti-lymphoma therapy - Pregnant or breastfeeding - Hypersensitivity to rituximab - Uncontrolled intercurrent illness - Receiving other study agents - HIV positive on combination antiretroviral therapy
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms